Patient characteristics at the time of diagnosis
| Characteristic . | Category . | Intensive-Therapy Group . | Control Group . |
|---|---|---|---|
| Median age (y) | 51 | 54 | |
| Male/female | 172/102 | 165/109 | |
| WHO performance status | 0-1 | 139 (52%) | 65 (45%) |
| 2-4 | 129 (48%) | 80 (55%) | |
| Missing data | 6 | 129 | |
| Stage (Durie and Salmon) | I | 6 (2%) | 16 (6%) |
| II | 76 (28%) | 104 (38%) | |
| III | 192 (70%) | 154 (56%) | |
| M-protein class | IgG | 169 (62%) | 157 (57%) |
| IgA | 66 (24%) | 48 (18%) | |
| IgD | 4 (1%) | 3 (1%) | |
| Light chains only | 35 (13%) | 65 (24%) | |
| Serum creatinine | > 200 μmol/L | 25 (9%) | 36 (13%) |
| Blood hemoglobin | < 100 g/L | 97 (35%) | 79 (29%) |
| Serum calcium | > 2.6 mmol/L | 86 (31%) | 77 (30%) |
| Serum β-2-microglobulin | < 4 mg/L | 136 (58%) | 62 (44%) |
| 4-8 mg/L | 59 (26%) | 52 (36%) | |
| > 8 mg/L | 35 (16%) | 29 (20%) | |
| Missing data | 48 | 131 | |
| Bone marrow plasma cells | > 25% | 140 (51%) | 124 (49%) |
| Advanced osteolytic lesions | 128 (47%) | 108 (40%) |
| Characteristic . | Category . | Intensive-Therapy Group . | Control Group . |
|---|---|---|---|
| Median age (y) | 51 | 54 | |
| Male/female | 172/102 | 165/109 | |
| WHO performance status | 0-1 | 139 (52%) | 65 (45%) |
| 2-4 | 129 (48%) | 80 (55%) | |
| Missing data | 6 | 129 | |
| Stage (Durie and Salmon) | I | 6 (2%) | 16 (6%) |
| II | 76 (28%) | 104 (38%) | |
| III | 192 (70%) | 154 (56%) | |
| M-protein class | IgG | 169 (62%) | 157 (57%) |
| IgA | 66 (24%) | 48 (18%) | |
| IgD | 4 (1%) | 3 (1%) | |
| Light chains only | 35 (13%) | 65 (24%) | |
| Serum creatinine | > 200 μmol/L | 25 (9%) | 36 (13%) |
| Blood hemoglobin | < 100 g/L | 97 (35%) | 79 (29%) |
| Serum calcium | > 2.6 mmol/L | 86 (31%) | 77 (30%) |
| Serum β-2-microglobulin | < 4 mg/L | 136 (58%) | 62 (44%) |
| 4-8 mg/L | 59 (26%) | 52 (36%) | |
| > 8 mg/L | 35 (16%) | 29 (20%) | |
| Missing data | 48 | 131 | |
| Bone marrow plasma cells | > 25% | 140 (51%) | 124 (49%) |
| Advanced osteolytic lesions | 128 (47%) | 108 (40%) |